F-Prime Capital

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

Nvelop Therapeutics is engaged in the development of advanced genetic medicines aimed at addressing severe genetic diseases. The company specializes in creating programmable delivery systems that enhance in vivo gene editing and facilitate the delivery of therapeutic cargo. By integrating epigenetic editing technologies with innovative delivery methods, Nvelop Therapeutics targets unmet medical needs, particularly in therapeutically relevant cells and tissues. Their focus on novel gene editing delivery technologies enables medical professionals to effectively deliver a range of therapeutic payloads, thereby improving treatment options for patients suffering from these challenging conditions.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Better Life Partners Inc. is a healthcare provider based in Hanover, New Hampshire, focused on supporting individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners utilizes technology to create personalized care plans that adapt to clients' needs, ensuring effective healthcare delivery through telehealth and community-based solutions. By integrating medical and behavioral healthcare, the company aims to address the complex needs of patients, providing comprehensive support to help them recover from addiction. Better Life Partners has additional offices across various locations in New Hampshire, reflecting its commitment to serving vulnerable populations.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Adcentrx Therapeutics is a biotechnology company dedicated to advancing the development of protein conjugate therapeutics aimed at treating cancer and other serious diseases. The company focuses on creating targeted therapies that leverage the precise targeting capabilities of biologics combined with the therapeutic effectiveness of small molecule payloads. Through its innovative approach, Adcentrx seeks to enhance patient treatment options, offering next-generation therapies that aim to improve outcomes for individuals facing life-threatening conditions.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Elucidata Corporation, founded in 2015 and headquartered in New Delhi, India, specializes in accelerating drug discovery through its proprietary SaaS platform, Polly. This platform transforms drug discovery by delivering machine learning-ready biomedical molecular data, supported by a vast repository of over 230,000 multi-omic datasets, with more than 50,000 datasets added monthly. Polly curates this data semi-automatically, enabling data-driven drug discovery teams to integrate proprietary and public biomedical data for machine learning applications. By adhering to the FAIR guidelines, Polly's Data Lakes provide exclusive access to curated multi-omics data, facilitating faster identification of therapeutic assets with a higher likelihood of clinical success. The platform has proven instrumental in detecting validated drug targets across various fields, including immunology, oncology, and metabolomic disorders. Elucidata collaborates with leading organizations such as Pfizer, Agios Pharmaceuticals, and Genentech, as well as over 35 research partners from prominent biopharma companies and research institutions, enhancing decision-making processes in drug research and development.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.

Castor is an international health-tech company founded by CEO Derk Arts, MD, Ph.D. Their cloud-based clinical data platform simplifies the entire clinical trial process, from recruitment to analysis, for researchers worldwide. More than 50,000 researchers across 90 countries are using Castor to supercharge their research. Castor’s platform has supported more than 4,000 commercial and academic studies that cover a broad range of therapeutic areas including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Researchers on the platform generate vast amounts of data from traditional and remote trials, and Castor recently reached milestones of 180,000,000 data points and 2,000,000 enrolled patients. Castor’s goal is to make the world’s research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.

Cohort’s solution enables Primary Care Providers (PCP) to significantly improve the scale, efficiency and outcomes of a new or existing Chronic Care Management (CCM) program while simultaneously providing them a powerful platform for clinical trial identification and enrollment.

J-Pharma is a pharmaceutical company focused on developing novel drugs through a human-genomic approach, specifically targeting cell membrane transporters associated with various diseases. The company aims to create selective agents for treating conditions such as cancer by developing anti-cancer drugs and PET diagnostic agents that interact with transporters like LAT1, which are linked to cancer cell growth. J-Pharma's research emphasizes the importance of understanding drug transporters to enhance the pharmacokinetics of new drug candidates. By discovering key transporters within the human body, J-Pharma seeks to advance diagnostic methods and improve treatment options, thereby contributing to global health and enhancing the quality of life for aging populations in industrialized countries.

Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives. DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data. There is currently little incentive for consumers to contribute their DNA and health information to a third party database. There are also multiple privacy, security, and trust issues that limit broad participation. The solution is LunaDNA. LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients with serious diseases. Its therapeutic portfolio includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, and glycogen storage disorder 1A, as well as therapies for ocular and central nervous system disorders. Beam's base editing technology allows for targeted modifications at a single base in the genome without creating double-stranded breaks in DNA, positioning it as a pioneer in the field of genetic medicine. The company's pipeline includes several programs, such as BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201, reflecting its commitment to advancing genetic therapies.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.

Metcela Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cardiac diseases. Founded in 2016 and based in Kawasaki, Japan, Metcela specializes in fibroblast-based treatments, particularly its lead asset, MTC001. This therapy utilizes VCAM-1-positive Cardiac Fibroblasts, which are derived from the patient's own heart cells. Rather than replacing damaged cells, the therapy enhances the body's natural healing processes to repair heart tissue and restore a favorable microenvironment. Through its research and development efforts, Metcela aims to offer patients an effective and affordable alternative for treating heart failure.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform includes a suite of integrated applications that allow scientists to design, share, and document experiments, as well as manage biological entities like plasmids and antibodies. Key features include Benchling Insights, which enables users to visualize and collaborate on structured data, and a biological registration system for inventory tracking. Benchling's solutions cater to a diverse range of applications such as gene therapy, vaccines, and industrial biotechnology, serving scientists in biotech, pharmaceutical, academic, and government sectors. Established in 2012 and based in San Francisco, the company aims to enhance the speed and collaboration of life science research by providing tools that streamline workflows and facilitate critical R&D decisions.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients with serious diseases. Its therapeutic portfolio includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, and glycogen storage disorder 1A, as well as therapies for ocular and central nervous system disorders. Beam's base editing technology allows for targeted modifications at a single base in the genome without creating double-stranded breaks in DNA, positioning it as a pioneer in the field of genetic medicine. The company's pipeline includes several programs, such as BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201, reflecting its commitment to advancing genetic therapies.

Tempest Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in developing small molecule therapeutics for cancer treatment. Founded in 2011, the company focuses on innovative therapies that enhance anti-tumor immunity and directly target tumor cells. Its pipeline includes several clinical-stage candidates, notably TPST-1120, which blocks the PPAR-alpha pathway to stimulate immune response, and TPST-8844, designed to inhibit an enzyme that allows tumor cells to evade immune detection. Additionally, Tempest Therapeutics is working on compounds that target prostaglandins to counteract immune suppression. By pursuing these mechanisms, the company aims to create effective treatments that harness the body's own immune system to combat cancer.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Promentis Pharmaceuticals discovers, develops, and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. Promentis Pharmaceuticals was founded in 2006 and is based in Milwaukee, Wisconsin.

Core Diagnostics is a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India. We aim to become the destination for all your high-end diagnostic needs.

Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.

Promentis Pharmaceuticals discovers, develops, and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. Promentis Pharmaceuticals was founded in 2006 and is based in Milwaukee, Wisconsin.

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.

Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

VYNE Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments for dermatological conditions. Its flagship product, AMZEEQ, is a topical minocycline designed for the treatment of inflammatory lesions associated with moderate-to-severe acne vulgaris in patients aged nine and older. VYNE is advancing several other products, including FMX103, which is in Phase III clinical trials for moderate-to-severe papulopustular rosacea, and FCD105, a topical combination foam currently in Phase II trials for acne vulgaris. Additionally, the company is developing Serlopitant, an oral NK1 receptor antagonist aimed at alleviating pruritus linked to conditions such as prurigo nodularis. Founded in 2003 and headquartered in Bridgewater, New Jersey, VYNE Therapeutics was previously known as Menlo Therapeutics Inc. before its name change in September 2020.

Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Precision BioSciences, Inc. is a biotechnology company based in Durham, North Carolina, focused on genome editing and the development of therapeutic products. Utilizing its proprietary ARCUS genome editing platform, the company aims to create innovative solutions for human diseases and food applications. Precision BioSciences operates through two primary segments: Therapeutic and Food. The Therapeutic segment is engaged in developing allogeneic CAR T immunotherapies, with several candidates in clinical trials targeting various types of cancers, including acute lymphoblastic leukemia and multiple myeloma. Additionally, the company is involved in in vivo gene correction activities and has collaborations for developing treatments for chronic Hepatitis B. The Food segment concentrates on creating nutrition products. Founded in 2006, Precision BioSciences is dedicated to translating advanced gene editing technology into impactful products across the life sciences.

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.

REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Blueprint Medicines is a biopharmaceutical company dedicated to developing targeted therapies for cancers and rare diseases driven by abnormal kinase activation. Founded in 2008 and based in Cambridge, Massachusetts, the company utilizes its proprietary Insights-to-Validation Platform and chemical library to create small molecule kinase inhibitors that address specific genomic drivers. Key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis, and pralsetinib for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. Additionally, fisogatinib is under investigation for advanced hepatocellular carcinoma, while BLU-782 targets fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with several pharmaceutical companies to enhance its research and development efforts.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Acacia Pharma Ltd. is a pharmaceutical company based in Cambridge, United Kingdom, dedicated to discovering and developing supportive care drugs primarily for cancer patients. The company’s product portfolio features APD405, an injectable formulation aimed at treating nausea and vomiting, APD209 for cancer cachexia, and APD421, an intravenous formulation for preventing and treating nausea and vomiting. Acacia Pharma also focuses on addressing cancer-related issues such as fatigue and xerostomia. Incorporated in 2006, Acacia Pharma aims to enhance the quality of care for patients undergoing medical treatments, including surgery and chemotherapy.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.

Lumere (previously Procured Health) is an organization comprised of clinicians, researchers, pharmacists, and strategic thought leaders focused on helping health systems eliminate unwarranted clinical variation and cut unnecessary costs—specifically related to device and drug selection and utilization. It was incorporated in 2012 and is based in Chicago, Illinois.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.

Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Blueprint Medicines is a biopharmaceutical company dedicated to developing targeted therapies for cancers and rare diseases driven by abnormal kinase activation. Founded in 2008 and based in Cambridge, Massachusetts, the company utilizes its proprietary Insights-to-Validation Platform and chemical library to create small molecule kinase inhibitors that address specific genomic drivers. Key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis, and pralsetinib for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. Additionally, fisogatinib is under investigation for advanced hepatocellular carcinoma, while BLU-782 targets fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with several pharmaceutical companies to enhance its research and development efforts.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.